Gene coding for erbin, and diagnostic and therapeutic uses thereof

• US 20040014055A1
• Filed: 06/05/2003
• Published: 01/22/2004
• Est. Priority Date: 04/07/2000
• Status: Abandoned Application

• Current Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), University of Michigan
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), University of Michigan
• Inventors: Borg, Jean-Paul, Margolis, Ben, Birnbaum, Daniel
• Application Number:
  US10/240,926
• Publication Number:
  US 20040014055A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

The invention concerns a novel gene, coding for a protein named Erbin (Erbb2 Interacting protein), which interacts with the intracellular part of ERBB2/HER-2 receptors, involved in particular in the development of cancers, the diagnostic and therapeutic uses of novel nucleotide sequences and identified amino acids.

Claims

4. Isolated nucleic acid comprising an isolated nucleic acid sequence chosen from amongst the sequence SEQ ID no. 5, or the sequence comprising the nucleotides 2347 to 2535 on SEQ ID no. 5.

5. Isolated polypeptide, comprising a sequence chosen from amongst:

a) the residues 1 to 501 of SEQ ID no. 2;

the residues 296 to 334 of SEQ ID no. 4;

b) the sequence SEQ ID no. 7;

c) the sequence SEQ ID no. 2 with a mutation of the histidine 1347 into leucine;

the sequence SEQ ID no. 2 with a mutation of the leucine 1291 into methionine and of the phenylalanine 1293 into isoleucine;

the sequence SEQ ID no. 2 with a mutation of the histidine 1347 into tyrosine and of the glycine 1348 into aspartic acid; and

the sequence SEQ ID no. 2 with a mutation of the threonine 1316 into asparagine and of the arginine 1317 into serine.

7. Isolated nucleic acid comprising a nucleotide sequence coding for the polypeptide of claim 5 or 6.

6. Isolated polypeptide, consisting of a sequence chosen from amongst:

the residues 1279 to 1371 of SEQ ID no. 2;

the residues 502 to 1278 of SEQ ID no. 2

the residues 914 to 1371 of SEQ ID no. 2; and

the residues 1212 to 1280 of SEQ ID no. 2.

11. Nucleic probe of which the sequence is chosen from amongst the sequence ID no. 8 or SEQ ID no. 9.

12. Nucleic trigger of which the sequence is chosen from amongst the sequence SEQ ID no. 10 to SEQ ID no. 20.

16-1. Method of diagnosis in vitro of a tumour or of a predisposition to develop a tumour, comprising placing at least one antibody directed against the polypeptide as defined in claim 1, 5 or 6 in contact with a biological specimen obtained from a sample of suspect cells taken from a patient, in conditions permitting the possible formation of specific immunological complexes between the polypeptide as defined in claim 1, 5 or 6 and the said antibody or antibodies and the detection and/or the quantification of the specific immunological complexes which may be formed.